<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id>
      <journal-id journal-id-type="publisher-id">MEDI</journal-id>
      <journal-title-group>
        <journal-title>Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0025-7974</issn>
      <issn pub-type="epub">1536-5964</issn>
      <publisher>
        <publisher-name>Wolters Kluwer Health</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27661051</article-id>
      <article-id pub-id-type="pmc">5044921</article-id>
      <article-id pub-id-type="doi">10.1097/MD.0000000000004942</article-id>
      <article-id pub-id-type="art-access-id">04942</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>5700</subject>
        </subj-group>
        <subj-group>
          <subject>Research Article</subject>
          <subject>Clinical Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Breast malignant phyllodes tumor with rare pelvic metastases and long-term overall survival</article-title>
        <subtitle>A case report and literature review</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Shan</surname>
            <given-names>Jinlan</given-names>
          </name>
          <degrees>MS</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Shizhen</given-names>
          </name>
          <degrees>MS</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Zhen</given-names>
          </name>
          <degrees>MS</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fu</surname>
            <given-names>Yanbiao</given-names>
          </name>
          <degrees>MD</degrees>
          <xref ref-type="aff" rid="aff2">
            <sup>b</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Ling</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="aff3">
            <sup>c</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Xiaochen</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <xref ref-type="aff" rid="aff1">
            <sup>a</sup>
          </xref>
          <xref>
            <sup>&#x2217;</sup>
          </xref>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Xie.</surname>
            <given-names>Maohua</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Department of Surgical Oncology and Cancer Institute, Key Laboratory of Cancer Prevention &amp; Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou</aff>
      <aff id="aff2"><label>b</label>Department of Pathology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China</aff>
      <aff id="aff3"><label>c</label>Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA.</aff>
      <author-notes id="cor1">
        <corresp><label>&#x2217;</label>Correspondence: Xiaochen Wang, Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China (e-mail: <email>wangxiaochen@zju.edu.cn</email>).</corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>9</month>
        <year>2016</year>
      </pub-date>
      <volume>95</volume>
      <issue>38</issue>
      <elocation-id>e4942</elocation-id>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>11</day>
          <month>7</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>8</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link></license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="medi-95-e4942.pdf"/>
      <abstract>
        <title>Abstract</title>
        <sec sec-type="background">
          <title>Background:</title>
          <p>Malignant phyllodes tumor (PT) is a rare fibro epithelial neoplasm of the breast, which is poor prognosis due to high risk of recurrence and distant metastasis.</p>
        </sec>
        <sec sec-type="methods">
          <title>Methods:</title>
          <p>We report a case of malignant PT. It had recurred locally five times, and the sixth relapse was occurred 54 months after first diagnosis, presenting a huge pelvic mass (14&#x200A;cm &#xD7; 11&#x200A;cm) by CT scan. Histopathological examination has demonstrated a metastatic phyllodes tumor. After postoperative chemotherapy treatment, a longer survival has been achieved, which is more than 72 months.</p>
        </sec>
        <sec sec-type="results">
          <title>Results:</title>
          <p>Our case report describes a breast PT with several local recurrences and a rare metastasis (pelvic cavity), but long-term overall survival was achieved after surgery and chemotherapy.</p>
        </sec>
        <sec sec-type="conclusion">
          <title>Conclusion:</title>
          <p>We conclude that trustworthy prognosticators that identify patients with excessive potential of aggressive clinical course should be explored. Moreover, proper treatment could prolong overall survival of metastatic PT patients.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>case report</kwd>
        <kwd>long-term survival</kwd>
        <kwd>malignant phyllodes tumor</kwd>
        <kwd>pelvic metastases</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <label>1</label>
      <title>Introduction</title>
      <p>Phyllodes tumors (PTs) are unique neoplastic lesions that are comprised of both stromal and epithelial components, and they account for 0.3% to 1% of breast tumors in women.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> PTs are subdivided into benign, borderline, and malignant categories according to histologic features.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Approximately 25% of PTs are considered malignancy,<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> and 20% to 50% of malignant PTs give rise to metastasis.<sup>[<xref rid="R3" ref-type="bibr">3</xref>&#x2013;<xref rid="R6" ref-type="bibr">6</xref>]</sup> Most of the cases, malignant PTs metastasize to lung, pleura, bone and soft tissue,<sup>[<xref rid="R6" ref-type="bibr">6</xref>&#x2013;<xref rid="R8" ref-type="bibr">8</xref>]</sup> rare metastatic sites were reported including liver,<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]</sup> brain,<sup>[<xref rid="R11" ref-type="bibr">11</xref>&#x2013;<xref rid="R13" ref-type="bibr">13</xref>]</sup> heart,<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> mesentery,<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> spleen,<sup>[<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>]</sup> kidney, adrenals, cervical,<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> pancreas,<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> uterus, thyroid,<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> skin.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup> Recurrence or metastasis of breast PTs predicts a shorter survival time, &lt;1 year.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> Here, we present a case of a female breast malignant PT patient with local recurrences and subsequent metastasis to the pelvic cavity and bone; in the end, the patient was expired after 72 months of follow-up.</p>
    </sec>
    <sec>
      <label>2</label>
      <title>Case report</title>
      <p>A 30-year-old female patient was admitted to the hospital complaining of a mass in her left breast for 3 months. No significant signs were observed in her past medical and family history. Physical examination revealed a mass (5 cm &#xD7; 5&#x200A;cm) with a clear border in the left breast. Then, the patient underwent partial mastectomy and histopathological examination revealed malignant PT.</p>
      <p>The patient had 5 recurrences in situ later and detailed descriptions were shown in Table <xref ref-type="table" rid="T1">1</xref>. Additionally, axillary lymph node dissection was performed in the third relapse because of axillary lymph node metastasis. In the following months, the patient was chosen to a routine follow-up procedure.</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Timeline.</p>
        </caption>
        <graphic xlink:href="medi-95-e4942-g001"/>
      </table-wrap>
      <p>Unexpectedly, 54 months after diagnosis, the patient came to our hospital complaining of abdominal distension. Computerized tomography (CT) scan of abdominal and pelvic revealed a colossal, lobulated, and well-defined mass in the pelvic, 14 &#xD7; 11&#x200A;cm in size (Fig. <xref ref-type="fig" rid="F1">1</xref>A). The pelvic mass was suspected as a metastasis of breast PT. Furthermore, <sup>18</sup>F-FDG positron emission tomography and computed tomography (FDG-PET/CT) were conducted and showed a tremendous mass with high metabolism in the pelvic cavity (Fig. <xref ref-type="fig" rid="F2">2</xref>A and B). Also, there was evidence of a thoracic vertebra and rib metastasis (Fig. <xref ref-type="fig" rid="F2">2</xref>C&#x2013;F). The patient was referred to our department and the pelvic tumorectomy was carried out. Intraoperative frozen section revealed the presence of malignant spindle tumor cells. Then, panhysterectomy was continually performed. Postoperative histopathologic examination demonstrated metastatic malignant PT (Fig. <xref ref-type="fig" rid="F3">3</xref>). Through Immunohistochemical staining, SMA, CD34 were positive and desmin, CD117, EMA, ER, PR, S-100, Bcl-2, NF, GFAP, and DOG-1 were negative. Postoperative CT scan showed clean excision of pelvic metastatic tumor without residue (Fig. <xref ref-type="fig" rid="F1">1</xref>B).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>CT scan showed an inhomogeneous density mass with clear border in the pelvic cavity (white arrow) (A). After pelvic tumorectomy, CT scan showed no residual tumor in the pelvic cavity (B). No recurrent lesions were detected in the CT scan after chemotherapy (C). Multiple fusion lesions were found in the pelvic cavity 3 months after chemotherapy (white arrow) (D). The recurrent lesion had shrunk to a small area with obvious enhancement after surgical treatment (E). CT scan displayed that ill-defined lesions increased (white arrow) (F). CT = computed tomography.</p>
        </caption>
        <graphic xlink:href="medi-95-e4942-g002"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>PET-CT obtained at baseline showed distant metastases involving the pelvic cavity (A, B), thoracic vertebra (C, D), and rib (E, F) (arrow). PET-CT = <sup>18</sup>F-FDG positron emission tomography-computed tomography.</p>
        </caption>
        <graphic xlink:href="medi-95-e4942-g003"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Histopathological examination with hematoxylin and eosin stain showed spindle cell tumor of the pelvic cavity. Microscopically, the tumor consisted of an epithelial and a cellular stromal component (A&#x200A;&#xD7;&#x200A;100, B&#x200A;&#xD7;&#x200A;200). Massive necrosis was also observed in the tumor (C&#x200A;&#xD7;&#x200A;40). The nuclei exhibited moderate atypia (D&#x200A;&#xD7;&#x200A;400).</p>
        </caption>
        <graphic xlink:href="medi-95-e4942-g004"/>
      </fig>
      <p>The patient received 4 courses of postoperative chemotherapy (doxorubicin hydrochloride 40&#x200A;mg/m<sup>2</sup> on days 1&#x2013;5, Ifosfamide 2&#x200A;g/m<sup>2</sup> on days 1&#x2013;5, per 21 days). Then, only doxorubicin hydrochloride (40&#x200A;mg/m<sup>2</sup> on days 1, per 21 day) was given for 3 courses later because of intolerable nausea and vomiting. Evaluating curative effect after the accomplishment of chemotherapy was stable disease (SD, Fig. <xref ref-type="fig" rid="F1">1</xref>C). The patient did not receive radiotherapy. Subsequently, the patient experienced pelvic metastases twice 3 months or 7 months after the chemotherapy (Fig. <xref ref-type="fig" rid="F1">1</xref>D and F). All of the metastatic lesions were palliative treated by operation (Fig. <xref ref-type="fig" rid="F1">1</xref>E).</p>
      <p>The patient died 72 months after diagnosis of PT.</p>
    </sec>
    <sec>
      <label>3</label>
      <title>Discussion</title>
      <p>The malignant PT which has a high tendency toward local recurrence and distant metastasis is uncommon in the breast. Distant metastasis developed at different time after the first diagnosis of breast PT. The average time to metastasis was 15 to 26 months;<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup> however, the patient in our case occurred metastasis 54 months after diagnosis. Most distant metastasis of malignant PTs present in lungs, pleura, bone, and soft tissue (Table <xref ref-type="table" rid="T2">2</xref>). Rare metastatic sites have also been showed in Table <xref ref-type="table" rid="T3">3</xref>. However, metastasis to pelvic cavity described in this case was not included based on our knowledge.</p>
      <table-wrap id="T2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Reported common metastatic sites for phyllodes tumor.</p>
        </caption>
        <graphic xlink:href="medi-95-e4942-g005"/>
      </table-wrap>
      <table-wrap id="T3" position="float">
        <label>Table 3</label>
        <caption>
          <p>Clinical characteristics, pathological findings, and follow-up of 20 patients with phyllodes tumor metastasize to rare sites.</p>
        </caption>
        <graphic xlink:href="medi-95-e4942-g006"/>
      </table-wrap>
      <p>Operation is the basic treatment of breast PT regardless of the nature of the tumor. Wide local excision with negative margins of 1 to 2&#x200A;cm is recommended. If negative margins cannot be obtained, then simple mastectomy is preferred. The efficacy between wide local excision and mastectomy is indistinct.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> Although the possibility of local recurrence declined in patients who underwent mastectomy, overall survival did not improve when perform mastectomy.<sup>[<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref>]</sup> It was unnecessary to carry out axillary lymph node dissection with breast PT if no clinically evident involvement of axillary nodes.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> Despite clean tumor resection and negative margin, local recurrence can hardly be avoided. The risk of relapse in malignant PTs was significantly greater than benign tumors.<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> In this case, the patient was performed partial mastectomy after initial diagnosis as PT. Consistent with the literatures reported, the patient relapsed after 17 months, subsequently, the patient experienced other 4 times local recurrence.</p>
      <p>Whether chemotherapy could improve disease-free survival (DFS) or overall survival (OS) for PT of the breast is controversial.<sup>[<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref>]</sup> There are no randomized clinical trials proving the effectiveness of chemotherapy in malignant PT. Morales-Vazquez suggested that adjuvant chemotherapy did not improve the 5-year recurrence-free survival in patients with breast malignant PTs after surgical resection.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> However, in the patients with metastasis PT, chemotherapy should be considered the optimal treatment.<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> Hawkins presented a case which received combination chemotherapy as soon as metastasis appeared had 61 months disease-free survival, which was longer than other available literatures.<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> Radiotherapy plays a major role in the prevention of postoperative recurrence of several solid tumors. While currently, there is no consensus on the role of radiotherapy in malignant PT.<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> Pandey et al<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> and Belkacemi et al<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> suggested that adjuvant radiotherapy after surgery had no significant impact on disease-free survival or overall survival. In the report from the Surveillance Epidemiology and End Results (SEER) Program on 821 malignant PTs, radiotherapy plus surgery predicted for worse cancer-specific survival compared with surgery alone.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup></p>
      <p>Local recurrence is a risk factor of tumor distant metastasis. Most distant metastasis of breast PT took place after local recurrence.<sup>[<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R26" ref-type="bibr">26</xref>]</sup> However, other investigators did not observe the association between local recurrence and systemic spread.<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> Moreover, local recurrence can be salvaged by secondary surgery.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> Whether the local recurrence is a predictive factor for metastasis of breast PT is still elusive.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> A study suggested that tumor size tended to be an independently predictive factor for local recurrence.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> Strong CEA expression in the epithelia correlated with local recurrence of PT of the breast, therefore, suitable to predict the clinical course of the disease.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup> In addition, genetic abnormalities were pointed out to be responsible for recurrences of PT, especially 1q gain mapped to 1q21&#x2013;23 region and 3p loss mapped to the FHIT gene in the 3p12&#x2013;14 region.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> Tumor distant metastasis is the main cause of survival threatening. As long as the breast PT progresses to distant metastasis, its prognosis is unfavorable, and median survival ranges from 5 to 24 months.<sup>[<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup> Our described patient gave rise to metastases after 54 months of first diagnosis and then died after 72 months. Microscopically, histology features of malignant PT are clear stromal cellular atypia, marked stromal overgrowth, infiltrating tumor margins, and &gt;10/10 HPF of mitotic activity. Stromal cellularity, stromal overgrowth, tumor margin, and mitotic activity were all significantly correlated with distant metastases.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> It has been noted that 87.5% of PTs which had a characterization of mitotic activity greater than 15/10 HPF finally metastasized.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> MiR-21 played a crucial role in the molecular pathogenesis of PT metastasis. It induced myofibroblast differentiation, subsequently regulated migration, and promoted metastasis.<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup> Autophagy-related protein LC3A expression in the stromal component of PT was significantly associated with distant metastasis.<sup>[<xref rid="R32" ref-type="bibr">32</xref>]</sup> Metastatic PTs had a remarkably higher stromal CD10 expression, and cases with negative CD10 expression did not metastasized.<sup>[<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref>]</sup> High expression of CD10, as a metalloprotease, might increase the potential of metastasis by providing tumors with the capacity of invading vessel walls.<sup>[<xref rid="R33" ref-type="bibr">33</xref>]</sup> However, these markers are still not powerful prediction in clinical practice.<sup>[<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R34" ref-type="bibr">34</xref>]</sup> It is important to identify some reliable factors to predict recurrence of PT and manage patients in early period.</p>
    </sec>
    <sec>
      <label>4</label>
      <title>Conclusion</title>
      <p>Current case represented a malignant breast PT with local recurrences and an extraordinary localization of metastasis (pelvic cavity), but the patient possessed of long-term survival following operation and chemotherapy. From the case report of our study, we proposed that reliable predictive factors should be explored to identify patients at high risk of local recurrence and distant metastasis. Although breast PTs have unfavorable prognosis, there is no standardized therapeutic strategy for it, so there is urgent need to perform well-designed prospective studies for investigating the roles of different strategies in treatment of breast PT.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="abbr">
        <p>Abbreviations: HPF = (high power field), PT = phyllodes tumor.</p>
      </fn>
      <fn fn-type="equal">
        <p>JS and SZ contributed equally to this study.</p>
      </fn>
      <fn fn-type="other">
        <p>The authors obtained written consent of the patient to describe her illness and publish this case report.</p>
      </fn>
      <fn fn-type="other">
        <p>Ethics committee approval is not included as it is commonly accepted that case reports do not require such approval. In our work, we did not use patient data that would allow identifying her. Patient agreed to all above diagnostic tests and treatment that was used.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>The authors have no funding and conflicts of interest to disclose.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <mixed-citation publication-type="book"><publisher-name>International Agency for Research on Cancer</publisher-name>, <person-group person-group-type="author"><name><surname>Lakhani</surname><given-names>SR</given-names></name></person-group>
<collab>Cancer IAfRo, Organization WH</collab>. <article-title>WHO Classification of Tumours of the Breast</article-title>. <year>2012</year>.</mixed-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangi</surname><given-names>AA</given-names></name><name><surname>Smith</surname><given-names>BL</given-names></name><name><surname>Gadd</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Surgical management of phyllodes tumors</article-title>. <source><italic>Arch Surg</italic></source>
<year>1999</year>; <volume>134</volume>:<fpage>487</fpage>&#x2013;<lpage>492</lpage>.<pub-id pub-id-type="pmid">10323420</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lakhani</surname><given-names>S</given-names></name><name><surname>Ellis</surname><given-names>I</given-names></name><name><surname>Schnitee</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>World Health Organisation Classification of Tumors of the Breast</article-title>. <year>2012</year>; <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>International Agency for Research on Cancer (IARC)</publisher-name>, <comment>142&#x2013;147</comment>.</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinfuss</surname><given-names>M</given-names></name><name><surname>Mitu&#x15B;</surname><given-names>J</given-names></name><name><surname>Duda</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>The treatment and prognosis of patients with phyllodes tumor of the breast: An analysis of 170 cases</article-title>. <source><italic>Cancer</italic></source>
<year>1996</year>; <volume>77</volume>:<fpage>910</fpage>&#x2013;<lpage>916</lpage>.<pub-id pub-id-type="pmid">8608483</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdalla</surname><given-names>H</given-names></name><name><surname>Sakr</surname><given-names>M</given-names></name></person-group>
<article-title>Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast</article-title>. <source><italic>J Egypt Natl Canc Inst</italic></source>
<year>2006</year>; <volume>18</volume>:<fpage>125</fpage>&#x2013;<lpage>133</lpage>.<pub-id pub-id-type="pmid">17496937</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapiris</surname><given-names>I</given-names></name><name><surname>Nasiri</surname><given-names>N</given-names></name><name><surname>A&#x2019;Hern</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast</article-title>. <source><italic>Eur J Surg Oncol</italic></source>
<year>2001</year>; <volume>27</volume>:<fpage>723</fpage>&#x2013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">11735168</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fou</surname><given-names>A</given-names></name><name><surname>Schnabel</surname><given-names>FR</given-names></name><name><surname>Hamele-Bena</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Long-term outcomes of malignant phyllodes tumors patients: an institutional experience</article-title>. <source><italic>Am J Surg</italic></source>
<year>2006</year>; <volume>192</volume>:<fpage>492</fpage>&#x2013;<lpage>495</lpage>.<pub-id pub-id-type="pmid">16978957</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Kim do</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Analysis of phyllodes tumor recurrence according to the histologic grade</article-title>. <source><italic>Breast Cancer Res Treat</italic></source>
<year>2013</year>; <volume>141</volume>:<fpage>353</fpage>&#x2013;<lpage>363</lpage>.<pub-id pub-id-type="pmid">24062207</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>YT</given-names></name><name><surname>Cai</surname><given-names>YC</given-names></name><etal/></person-group>
<article-title>Predictive factors for the local recurrence and distant metastasis of phyllodes tumors of the breast: a retrospective analysis of 192 cases at a single center</article-title>. <source><italic>Chin J Cancer</italic></source>
<year>2014</year>; <volume>33</volume>:<fpage>492</fpage>&#x2013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">25104281</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norris</surname><given-names>HJ</given-names></name><name><surname>Taylor</surname><given-names>HB</given-names></name></person-group>
<article-title>Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases</article-title>. <source><italic>Cancer</italic></source>
<year>1967</year>; <volume>20</volume>:<fpage>2090</fpage>&#x2013;<lpage>2099</lpage>.<pub-id pub-id-type="pmid">4294565</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>RM</given-names></name><name><surname>Evans</surname><given-names>HL</given-names></name></person-group>
<article-title>Cystosarcoma phyllodes. A clinicopathologic study of 26 cases</article-title>. <source><italic>Cancer</italic></source>
<year>1986</year>; <volume>58</volume>:<fpage>2282</fpage>&#x2013;<lpage>2289</lpage>.<pub-id pub-id-type="pmid">3019505</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>RH</given-names></name><name><surname>Frankel</surname><given-names>KA</given-names></name><name><surname>Davis</surname><given-names>RL</given-names></name><etal/></person-group>
<article-title>Metastatic cystosarcoma phyllodes. A report of 2 cases presenting with neurological symptoms</article-title>. <source><italic>Cancer</italic></source>
<year>1978</year>; <volume>41</volume>:<fpage>1179</fpage>&#x2013;<lpage>1187</lpage>.<pub-id pub-id-type="pmid">205335</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakant</surname><given-names>P</given-names></name><name><surname>Chakravarthy</surname><given-names>S</given-names></name><name><surname>Cherian</surname><given-names>JA</given-names></name><etal/></person-group>
<article-title>Challenges in management of phyllodes tumors of the breast: a retrospective analysis of 150 patients</article-title>. <source><italic>Indian J Cancer</italic></source>
<year>2013</year>; <volume>50</volume>:<fpage>345</fpage>&#x2013;<lpage>348</lpage>.<pub-id pub-id-type="pmid">24369215</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>RE</given-names></name><name><surname>Schofield</surname><given-names>JB</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes</article-title>. <source><italic>Cancer</italic></source>
<year>1992</year>; <volume>69</volume>:<fpage>141</fpage>&#x2013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">1309302</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>RJ</given-names></name><name><surname>Wells</surname><given-names>WA</given-names></name><name><surname>Mitchell</surname><given-names>SE</given-names></name><etal/></person-group>
<article-title>A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors</article-title>. <source><italic>Ann Surg Oncol</italic></source>
<year>2009</year>; <volume>16</volume>:<fpage>2288</fpage>&#x2013;<lpage>2294</lpage>.<pub-id pub-id-type="pmid">19424757</pub-id></mixed-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>OK</given-names></name><name><surname>Lee</surname><given-names>CM</given-names></name><name><surname>Tward</surname><given-names>JD</given-names></name><etal/></person-group>
<article-title>Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program</article-title>. <source><italic>Cancer</italic></source>
<year>2006</year>; <volume>107</volume>:<fpage>2127</fpage>&#x2013;<lpage>2133</lpage>.<pub-id pub-id-type="pmid">16998937</pub-id></mixed-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Cheng</surname><given-names>SP</given-names></name><name><surname>Tzen</surname><given-names>CY</given-names></name><etal/></person-group>
<article-title>Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases</article-title>. <source><italic>J Surg Oncol</italic></source>
<year>2005</year>; <volume>91</volume>:<fpage>185</fpage>&#x2013;<lpage>194</lpage>.<pub-id pub-id-type="pmid">16118768</pub-id></mixed-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvadori</surname><given-names>B</given-names></name><name><surname>Cusumano</surname><given-names>F</given-names></name><name><surname>Bo</surname><given-names>RD</given-names></name><etal/></person-group>
<article-title>Surgical treatment of phyllodes tumors of the breast</article-title>. <source><italic>Cancer</italic></source>
<year>1989</year>; <volume>63</volume>:<fpage>2532</fpage>&#x2013;<lpage>2536</lpage>.<pub-id pub-id-type="pmid">2541890</pub-id></mixed-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>RJ</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors</article-title>. <source><italic>Breast Cancer Res Treat</italic></source>
<year>1999</year>; <volume>57</volume>:<fpage>291</fpage>&#x2013;<lpage>295</lpage>.<pub-id pub-id-type="pmid">10617306</pub-id></mixed-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>R</given-names></name><name><surname>Schofield</surname><given-names>J</given-names></name><name><surname>Wiltshaw</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Chemotherapy for metastatic cystosarcoma phylloides: ifosfamide is an active drug</article-title>. <source><italic>Cancer</italic></source>
<year>1992</year>; <volume>69</volume>:<fpage>2271</fpage>&#x2013;<lpage>2275</lpage>.<pub-id pub-id-type="pmid">1314127</pub-id></mixed-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales-V&#xE1;squez</surname><given-names>F</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Broglio</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast</article-title>. <source><italic>Breast J</italic></source>
<year>2007</year>; <volume>13</volume>:<fpage>551</fpage>&#x2013;<lpage>556</lpage>.<pub-id pub-id-type="pmid">17983394</pub-id></mixed-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitus</surname><given-names>JW</given-names></name><name><surname>Blecharz</surname><given-names>P</given-names></name><name><surname>Walasek</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Treatment of patients with distant metastases from phyllodes tumor of the breast</article-title>. <source><italic>World J Surg</italic></source>
<year>2016</year>; <volume>40</volume>:<fpage>323</fpage>&#x2013;<lpage>328</lpage>.<pub-id pub-id-type="pmid">26464157</pub-id></mixed-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosravi-Shahi</surname><given-names>P</given-names></name></person-group>
<article-title>Management of non metastatic phyllodes tumors of the breast: review of the literature</article-title>. <source><italic>Surg Oncol</italic></source>
<year>2011</year>; <volume>20</volume>:<fpage>e143</fpage>&#x2013;<lpage>e148</lpage>.<pub-id pub-id-type="pmid">21609854</pub-id></mixed-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>M</given-names></name><name><surname>Mathew</surname><given-names>A</given-names></name><name><surname>Kattoor</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Malignant phyllodes tumor</article-title>. <source><italic>Breast J</italic></source>
<year>2001</year>; <volume>7</volume>:<fpage>411</fpage>&#x2013;<lpage>416</lpage>.<pub-id pub-id-type="pmid">11843853</pub-id></mixed-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belkacemi</surname><given-names>Y</given-names></name><name><surname>Bousquet</surname><given-names>G</given-names></name><name><surname>Marsiglia</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Phyllodes tumor of the breast</article-title>. <source><italic>Int J Radiat Oncol Biol Phys</italic></source>
<year>2008</year>; <volume>70</volume>:<fpage>492</fpage>&#x2013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">17931796</pub-id></mixed-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moffat</surname><given-names>CJC</given-names></name><name><surname>Pinder</surname><given-names>SE</given-names></name><name><surname>Dixon</surname><given-names>AR</given-names></name><etal/></person-group>
<article-title>Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases</article-title>. <source><italic>Histopathology</italic></source>
<year>1995</year>; <volume>27</volume>:<fpage>205</fpage>&#x2013;<lpage>218</lpage>.<pub-id pub-id-type="pmid">8522284</pub-id></mixed-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>O</given-names></name><name><surname>Brentani</surname><given-names>MM</given-names></name><name><surname>Goes</surname><given-names>JCS</given-names></name><etal/></person-group>
<article-title>Carcinoembryonic antigen. A possible predictor of recurrence in cystosarcoma phyllodes</article-title>. <source><italic>Cancer</italic></source>
<year>1986</year>; <volume>57</volume>:<fpage>1042</fpage>&#x2013;<lpage>1045</lpage>.<pub-id pub-id-type="pmid">3002592</pub-id></mixed-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>GM</given-names></name><name><surname>Niu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>HJ</given-names></name></person-group>
<article-title>Phyllodes tumor of the breast: an update</article-title>. <source><italic>Breast Cancer</italic></source>
<year>2010</year>; <volume>17</volume>:<fpage>29</fpage>&#x2013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">19434472</pub-id></mixed-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Roos</surname><given-names>WK</given-names></name><name><surname>Kaye</surname><given-names>P</given-names></name><name><surname>Dent</surname><given-names>DM</given-names></name></person-group>
<article-title>Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast</article-title>. <source><italic>Brit J Surg</italic></source>
<year>1999</year>; <volume>86</volume>:<fpage>396</fpage>&#x2013;<lpage>399</lpage>.<pub-id pub-id-type="pmid">10201787</pub-id></mixed-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>MM</given-names></name></person-group>
<article-title>Cystosarcoma phyllodes of the breast: histologic features, flow cytometric analysis, and clinical correlations</article-title>. <source><italic>Mod Pathol</italic></source>
<year>1992</year>; <volume>5</volume>:<fpage>232</fpage>&#x2013;<lpage>239</lpage>.<pub-id pub-id-type="pmid">1323101</pub-id></mixed-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>C</given-names></name><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>miR-21 induces myofibroblast differentiation and promotes the malignant progression of breast phyllodes tumors</article-title>. <source><italic>Cancer Res</italic></source>
<year>2014</year>; <volume>74</volume>:<fpage>4341</fpage>&#x2013;<lpage>4352</lpage>.<pub-id pub-id-type="pmid">24980553</pub-id></mixed-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Jung</surname><given-names>WH</given-names></name><name><surname>Koo</surname><given-names>JS</given-names></name></person-group>
<article-title>Expression of autophagy-related proteins in phyllodes tumor</article-title>. <source><italic>Int J Clin Exp Pathol</italic></source>
<year>2013</year>; <volume>6</volume>:<fpage>2145</fpage>&#x2013;<lpage>2156</lpage>.<comment>09/15</comment>.<pub-id pub-id-type="pmid">24133593</pub-id></mixed-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Masri</surname><given-names>M</given-names></name><name><surname>Darwazeh</surname><given-names>G</given-names></name><name><surname>Sawalhi</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Phyllodes tumor of the breast: role of CD10 in predicting metastasis</article-title>. <source><italic>Ann Surg Oncol</italic></source>
<year>2012</year>; <volume>19</volume>:<fpage>1181</fpage>&#x2013;<lpage>1184</lpage>.<pub-id pub-id-type="pmid">22006372</pub-id></mixed-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariq</surname><given-names>MU</given-names></name><name><surname>Haroon</surname><given-names>S</given-names></name><name><surname>Kayani</surname><given-names>N</given-names></name></person-group>
<article-title>Role of CD10 immunohistochemical expression in predicting aggressive behavior of phylloides tumors</article-title>. <source><italic>Asian Pac J Cancer Prev</italic></source>
<year>2015</year>; <volume>16</volume>:<fpage>3147</fpage>&#x2013;<lpage>3152</lpage>.<pub-id pub-id-type="pmid">25921112</pub-id></mixed-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohn-Cedermark</surname><given-names>G</given-names></name><name><surname>Rutqvist</surname><given-names>LE</given-names></name><name><surname>Rosendahl</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients</article-title>. <source><italic>Cancer</italic></source>
<year>1991</year>; <volume>68</volume>:<fpage>2017</fpage>&#x2013;<lpage>2022</lpage>.<pub-id pub-id-type="pmid">1655234</pub-id></mixed-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asoglu</surname><given-names>O</given-names></name><name><surname>Karanlik</surname><given-names>H</given-names></name><name><surname>Barbaros</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Malignant phyllode tumor metastatic to the duodenum</article-title>. <source><italic>World J Gastroenterol</italic></source>
<year>2006</year>; <volume>12</volume>:<fpage>1649</fpage>&#x2013;<lpage>1651</lpage>.<pub-id pub-id-type="pmid">16570365</pub-id></mixed-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczmarek-Borowska</surname><given-names>B</given-names></name><name><surname>Bukala</surname><given-names>A</given-names></name><name><surname>Syrek-Kaplita</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>A rare case of breast malignant phyllodes tumor with metastases to the kidney: case report</article-title>. <source><italic>Medicine</italic></source>
<year>2015</year>; <volume>94</volume>:<fpage>e1312</fpage>.<pub-id pub-id-type="pmid">26287414</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
